- Home
- PGY vs DNTH Comparison
PGY vs DNTH Comparison
Compare PGY & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGY | DNTH |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | 518 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 928.4M | 1.9B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | PGY | DNTH |
|---|---|---|
| Price | $11.27 | $81.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | $34.50 | ★ $123.09 |
| AVG Volume (30 Days) | ★ 2.6M | 1.1M |
| Earning Date | 05-06-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | $14.27 | N/A |
| Revenue Next Year | $14.19 | $30.33 |
| P/E Ratio | $13.54 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.50 | $13.37 |
| 52 Week High | $44.99 | $88.45 |
Technical Indicators
Market Signals| Indicator | PGY | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 42.41 | 68.17 |
| Support Level | $10.46 | $33.94 |
| Resistance Level | $25.47 | $88.45 |
| Average True Range (ATR) | 0.57 | 4.59 |
| MACD | 0.33 | -0.41 |
| Stochastic Oscillator | 53.29 | 46.03 |
Price Performance
Historical ComparisonAbout PGY Pagaya Technologies Ltd.
Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.